Nibedita Patro

A Phase III, Open-Label, Single-Arm, Multicentric Study of Tildrakizumab in Indian Patients with Moderate-to-Severe Plaque Psoriasis

Moderate-to-severe plaque psoriasis is a chronic inflammatory disease linked to significant morbidity and reduced quality of life (QoL). Prospective data on interleukin-23 (IL-23) inhibitors in Indian patients remain limited. This phase III, open-label, multicentre, single-arm br...